Technology platforms for pharmacogenomic diagnostic assays
Technology platforms for pharmacogenomic diagnostic assays
复制标题
DOI：
10.1038/nrd1496
复制
发表时间：
2004-09-01
影响因子：
120.1
通讯作者：
Koch, WH
中科院分区：
文献类型：
--
作者：
Koch, WH
对影响药物反应的基因组变异的理解的快速进展，以及多重检测技术的发展，正在共同形成新的体外诊断检测的基础。这些分子诊断测定有望指导许多疾病的治疗，告知医生需要差异化治疗的疾病的分子亚型，哪种药物最有可能有效控制疾病，以及哪些个体患者对特定药物治疗出现不良反应的风险最高。本文回顾了此类检测中最广泛使用的技术和平台的一些相对优势和局限性。
Rapid advances in the understanding of genomic variation affecting drug responses, and the development of multiplex assay technologies, are converging to form the basis for new in vitro diagnostic assays. These molecular diagnostic assays are expected to guide the therapeutic treatment of many diseases, by informing physicians about molecular subtypes of disease that require differential treatment, which drug has the greatest probability of effectively managing the disease, and which individual patients are at the highest risk of experiencing adverse reactions to a given drug therapy. This article reviews some of the relative strengths and limitations of the most widely used technologies and platforms for such assays.